Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Immunotherapy in Oral Squamous Cell Carcinoma

Immunotherapy in Oral Squamous Cell Carcinoma

Singh, Akanchha
Gupta, Shalini
Panwar, Payal

Paperback

Medical Reference

ISBN10: 6205632411
ISBN13: 9786205632413
Publisher: LAP Lambert Academic Publishing
Published: May 30 2025
Pages: 108
Weight: 0.34
Height: 0.26 Width: 6.00 Depth: 9.00
Language: English
Immunotherapy has emerged as a promising treatment modality for oral squamous cell carcinoma (OSCC), especially in advanced and recurrent cases where conventional therapies offer limited survival benefits. By harnessing the body's immune system, immunotherapeutic approaches such as immune checkpoint inhibitors-particularly anti-PD-1 agents like nivolumab and pembrolizumab-have shown improved overall survival and quality of life in select OSCC patients, as demonstrated in landmark trials like KEYNOTE-048 and CheckMate 141. Other strategies, including cancer vaccines, adoptive cell therapy, cytokine therapy, and oncolytic viruses, are under investigation but have yet to achieve widespread clinical use. Despite these advances, challenges such as low response rates, immune-related adverse events, tumor heterogeneity, and resistance mechanisms limit the efficacy of immunotherapy. Biomarkers like PD-L1 expression, tumor mutational burden, and immune gene signatures are being explored to guide patient selection and predict response. Combination therapies with chemotherapy, radiotherapy, or other immunomodulators are being developed to enhance outcomes.

1 different editions

Also available

Also from

Singh, Akanchha

View All

Also in

Medical Reference

View All